Summary.-In a retrospective study the postoperative time courses of CEA in colorectal cancer patients with recurrent disease were analysed. In 87/114 cases with increasing concentrations of circulating CEA under close follow-up a linear relationship between log CEA and time could be established during disease recurrence. The individual doubling times of the serum CEA concentration in the log CEA period were calculated and found to cover distinct ranges dependent on the diagnosis of disease recurrence. The CEA doubling times concomitant with local recurrence or second primary carcinomas ranged from 142 to 868 days, visceral metastasis other than liver metastasis from 47 to 231 days and liver metastasis from 10 to 102 days. Patients with bone metastases exhibited CEA doubling times of 54-60 days and a patient with brain metastasis had a CEA doubling time of 598 days.
POSTOPERATIVE MONITORING of circulating carcinoembryonic antigen (CEA) in patients with resected colorectal cancer is often used for the early detection of recurrent cancer. Consecutively rising CEA concentrations in the blood generally reflect disease recurrence and the rates of increase of the CEA concentrations can be used to discriminate between localized recurrence and metastatic spread (Staab et al., 1978; Wood et al., 1980; Steele et al., 1980) . A more precise characterization of the rate of CEA increase in relation to tumour development is indicated in recent studies of xenotransplants into nude mice using CEA-releasing human colorectal tumour cell lines. Tumour growth correlated well with a concomitant increase of circulating CEA during the logarithmic growth phase but showed a marked dissociation when the tumour growth rate slowed down. The rate of CEA increase during the logarithmic growth phase of the tumour allowed the doubling time of the serum CEA concentration to be calculated (Staab & Anderer, 1981 . Similar findings were reported for nude mice xenografted with alpha-fetoprotein (AFP)-producinghuman teratomas (Raghavan et al., 1980) .
The doubling time of a circulating tumour marker appears to have a prognostic value since the rate of increase of circulating AFP in patients with hepatocellular carcinoma was exponential and the AFP doubling times correlated positively with the survival of the patients (Johnson & Williams, 1980 In the present study we examined retrospectively the postoperative CEA time courses of colorectal cancer patients with recurrent disease who have been registered since 1974. The aim of the study was to establish increases of circulating CEA which exhibit a linear relationship between log CEA and time, to calculate CEA doubling times for the periods of logarithmic CEA increase and to correlate CEA doubling times with diagnosis of disease recurrence and survival of the patients.
PATIENTS AND METHODS
Patieits.-During the routine postoperative follow-up of patients with resected primary colorectal carcinoma, which included serum CEA determination and clinical examination every 2-3 months, we recorded 114 patients with recurrent disease who could be closely followed up. In most cases (87/114) the patients exhibited a distinct phase of logarithmic increase of circulating CEA during disease recurrence, in 21/114 patients the CEA time course was not logarithmical or was not well established due to partly missing CEA determinations and 6/114 patients were CEA-niegative throughout the entire surveillance.
Diagnosis of recurrence and metastasis was established clinically by endoscopy, radiological investigations, radioisotopic scanning, sonography and computerized tomography, or by explorative laparotomy or second-look surgery. Liver metastases generally appeared within 12 months after primary resection. At the time of diagnosis of metastases the patients were free of any complaints. Some of the patients received treatment with 5-fluorouracil (5-FU), ftorafur, or a combination of vincristine, adriblastin and 1,3-bis(2-chloroethyl-1-nitrosourea) (BCNU) or 5-FU; others underwent second-look surgery and/or radiotherapy or chemotherapy. Some of the patients had agreed to an adjuvant postoperative treatment based on an active specific immunotherapy schedule with chemically modified CEA using 3 single injections at Days 10, 40 and 130 after primary resection (data to be published).
A computerized recall program was developed to keep contact with the patients. In cases of death not registered in the clinic, confirmation was obtained from the family doctor, the relatives of the patient or the local community administration.
Serum CEA concentrations were assayed with the CEA-Roche-RIA test kit (HoffmanLaRoche, Basel, Switzerland) using only the indirect method. When CEA concentrations were > 20 ,ug/l the sera were prediluted with normal sera. Our own control sera were used to standardize the CEA assay throughout the investigation (Staab et al., 1980 Most of our patients with recurrent disease (59/87) had developed liver metastases and 37/59 did not receive any further treatment. The serum CEA of these patients showed exponential increases which, in many cases, were maintained until death. In the other cases the CEA curves ended in a plateau with occasional decreases or increases. In Fig.  1 (a) the change of serum CEA with time is depicted and given as a semilogarithmic plot in Fig. 1(b) .
Individual CEA doubling times were calculated for the 37 patients using the periods of linear relationship between log CEA and time. In Table I doubling times are listed for 33 patients who developed liver metastasis but received no further treatment and died. In addition, the duration of the log CEA phase and the time from the initial CEA increase of the log phase until death are given in days as well as in multiples of the individual CEA doubling time for each patient. The CEA doubling times ranged from 10 to 102 days. It can be seen from Table I that the survival time after the initial log CEA rise increased with increasing CEA doubling time. In Fig. 2 Fig. 3(a), (b) .
Fourteen of these 24 patients received treatment of recurrent disease or underwent second-look surgery. In Table III 14 cases of local recurrence exhibiting a log CEA phase in the CEA time course. Six patients underwent second-look surgery and 3/6 remained disease-free. All others showed further disease progression and the corresponding CEA time courses exhibited biphasic log CEA slopes. The CEA time courses of 2 selected cases are given in Fig. 4 . The calculated individual CEA doubling times and the duration of the log CEA phase of local recurrence are listed together with the site of recurrence and the diagnosis of disease progression (Table  IV) . The CEA doubling times ranged from 142 to 868 days. Only the CEA doubling time of a developing brain metastasis (598 days) was comparable with the higher CEA doubling times of local recurrence. In this special case local recurrence was definitely excluded by a preceding negative second-look operation.
DISCUSSION
The data obtained from our retrospective study of the postoperative CEA time courses of colorectal cancer patients with recurrent disease disclosed two relationships. (1) (Raghavan et al., 1980; days. The individual CEA doubling times correlated positively with survival of the patients, calculated from the data of initial log CEA increase, and the untreated patients showed a mean survival of 7 0 individual CEA doubling times + 1-8. At the beginning of the exponential increase of circulating CEA and subsequently at the time of diagnosis the patients usually were symptom free, independent of CEA doubling time. Assuming that the CEA increase also correlated with tumour volume in man, survival might be limited by a critical tumour burden leading to secondary complications in the liver. Survival expressed in multiples of the individual CEA doubling times also proved to reflect directly the effect of treatment of liver metastasis on tumour development and survival.
For patients with visceral metastases other than liver metastases and no further treatment, a correlation between CEA doubling time and survival could not be established. This could be due to the limited number of patients in this group or more probably to the possibility that CEAreleasing cells in these metastatic cases were not representative of the exacerbation of malignant disease which might entail tumour cells not releasing CEA. Furthermore, the mean survival of these patients, expressed in multiples of CEA doubling times, were distinctly shorter than for patients developing liver metastasis possibly due to secondary complications leading to serious damage of normal physiological functions earlier during tumour development. In a recent report (Toth et al., 1982) it was demonstrated that CEA is rapidly removed from circulation by the liver and therefore distinct impairment of liver function might influence clearance of CEA giving rise to shorter CEA doubling times.
The question whether the correlation between CEA doubling times and survival in patients with untreated liver metastasis is based on CEA release from proliferating metastatic cells or on failure of CEA clearance by the liver or on both mech-anisms cannot be answered presently. Further investigations on the biochemical regulation of CEA release, degradation and clearance are necessary.
The findings obtained in our retrospective study need confirmation by a prospective study randomized with respect to other prognostic criteria including performance status at the start of the exponential CEA increase. However, since CEA doubling times predicted survival in colorectal cancer patients with liver metastasis who were not treated, clinical trials claiming improvements in overall survival should be corrected for any imbalance in distribution of CEA doubling times.
